HX011 / HanX Biopharma - LARVOL DELTA

Discovery of HX011, a novel OX40 mAb, for potential cancer immunotherapy (AACR 2023) - "In another word, HX011 is similar to BMS-986178 for the first two assays, but contrastingly different for the third assay. In vivo pharmacology modeling of HX011 in the humanized syngeneic CRC model, MC38, where syngeneic C57BL/6 mouse mice were knocked in with huOX40 (“HuGEMM-OX40”), demonstrated strong anti-tumor activity (TGI ~100% at 1 mg/kg, twice weekly). HX011 is being further investigated as a potential new immunotherapy for the treatment of cancers."

Oncology • BCL2L1 • BIRC5 • CTLA4 • FOXP3